Institutional members access full text with Ovid®

Share this article on:

“Rise and fall” of hormone therapy in postmenopausal women with cardiovascular disease

Maas, Angela H.E.M. MD1; van der Schouw, Yvonne T. PhD2; Grobbee, Diederick E. MD, PhD2; van der Graaf, Yolanda MD, PhD2

doi: 10.1097/01.GME.0000087980.28957.86
Personal Perspective

Whereas observational data for postmenopausal women using hormone therapy (HT) have shown a protective effect against cardiovascular disease, prospective, randomized trials have demonstrated a harmful effect on the vascular system.

This study describes the effects of HT on lipids, hemostatic parameters, inflammation, and the vascular wall. Reasons for the different results of observational and experimental studies of HT are postulated. The timing of hormonal supplementation seems crucial. Used chronically, HT has no harmful effects; however, first-time use of HT after a recent cardiovascular event results in an early increase in adverse cardiovascular events. In most observational studies, women started HT for postmenopausal symptoms, whereas in experimental studies, women started HT 10 to 20 years or longer after menopause.

Cumulative evidence supports the hypothesis that HT has more effect in maintaining vascular health than in alleviating endothelial dysfunction. HT has not proven beneficial in the long term in women at risk of a cardiovascular event. The interval between menopause and the start of HT plays a crucial role in the effectiveness of HT in the vascular system.

From the 1Department of Cardiology, Isala Klinieken, Zwolle, the Netherlands; and the 2Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands.

Received March 6, 2003; revised and accepted June 25, 2003.

Address correspondence to: A.H.E.M. Maas, cardiologist, Isala Klinieken, Department of Cardiology, Dr. van Heesweg 2, 8025 AB Zwolle, The Netherlands. E-mail: a.maas@diagram-zwolle.nl.

©2004The North American Menopause Society